{"entity":{"type":"insider","cik":"0001910456","url":"/insider/0001910456","json_url":"/insider/0001910456.json","name":"Lynx1 Capital Management LP","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":34,"n_filings":16,"first":"2023-06-02","last":"2026-08-13","span_basis":"filed_date"},"name_variants":[{"name":"Lynx1 Capital Management LP","source":"filing","n_filings":16,"first_seen":"2023-06-02","last_seen":"2026-08-13"}],"transactions":[{"id":9205846,"accession":"0000902664-26-003434","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-26-003434","line_url":"/filing/0000902664-26-003434#line-2","is_derivative":false,"issuer_cik":"0001703647","issuer_name":"Korro Bio, Inc.","issuer_ticker":"KRRO","issuer_name_source":null,"issuer_url":"/issuer/0001703647","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1462.0,"shares_display":"1,462","price_per_share":13.1869,"price_display":"13.19","price_state":"stated","total_value":19279.2478,"total_display":"19,279.25","total_whole":"19,279","shares_owned_after":1544980.0,"shares_owned_after_display":"1,544,980","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-10","filed_date":"2026-08-13","scope":"insider"},{"id":9205845,"accession":"0000902664-26-003434","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-26-003434","line_url":"/filing/0000902664-26-003434#line-1","is_derivative":false,"issuer_cik":"0001703647","issuer_name":"Korro Bio, Inc.","issuer_ticker":"KRRO","issuer_name_source":null,"issuer_url":"/issuer/0001703647","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5222.0,"shares_display":"5,222","price_per_share":11.3998,"price_display":"11.40","price_state":"stated","total_value":59529.7556,"total_display":"59,529.76","total_whole":"59,530","shares_owned_after":1543518.0,"shares_owned_after_display":"1,543,518","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-06","filed_date":"2026-08-13","scope":"insider"},{"id":5780879,"accession":"0000902664-26-002945","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-26-002945","line_url":"/filing/0000902664-26-002945#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50055.0,"shares_display":"50,055","price_per_share":4.1175,"price_display":"4.12","price_state":"stated","total_value":206101.4625,"total_display":"206,101.46","total_whole":"206,101","shares_owned_after":673759.0,"shares_owned_after_display":"673,759","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-06-25","filed_date":"2026-06-29","scope":"insider"},{"id":5955113,"accession":"0000902664-26-001845","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-26-001845","line_url":"/filing/0000902664-26-001845#line-1","is_derivative":false,"issuer_cik":"0001703647","issuer_name":"Korro Bio, Inc.","issuer_ticker":"KRRO","issuer_name_source":null,"issuer_url":"/issuer/0001703647","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":520.0,"shares_display":"520","price_per_share":10.6,"price_display":"10.60","price_state":"stated","total_value":5512.0,"total_display":"5,512.00","total_whole":"5,512","shares_owned_after":1538296.0,"shares_owned_after_display":"1,538,296","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-02","scope":"insider"},{"id":4337319,"accession":"0000902664-25-005396","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-25-005396","line_url":"/filing/0000902664-25-005396#line-3","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6232.0,"shares_display":"6,232","price_per_share":0.8989,"price_display":"0.90","price_state":"stated","total_value":5601.9448,"total_display":"5,601.94","total_whole":"5,602","shares_owned_after":8019148.0,"shares_owned_after_display":"8,019,148","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-23","filed_date":"2025-12-23","scope":"insider"},{"id":4337315,"accession":"0000902664-25-005396","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-25-005396","line_url":"/filing/0000902664-25-005396#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75500.0,"shares_display":"75,500","price_per_share":0.9,"price_display":"0.90","price_state":"stated","total_value":67950.0,"total_display":"67,950.00","total_whole":"67,950","shares_owned_after":8012916.0,"shares_owned_after_display":"8,012,916","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-22","filed_date":"2025-12-23","scope":"insider"},{"id":4337310,"accession":"0000902664-25-005396","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-005396","line_url":"/filing/0000902664-25-005396#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":80069.0,"shares_display":"80,069","price_per_share":0.8989,"price_display":"0.90","price_state":"stated","total_value":71974.0241,"total_display":"71,974.02","total_whole":"71,974","shares_owned_after":7937416.0,"shares_owned_after_display":"7,937,416","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-19","filed_date":"2025-12-23","scope":"insider"},{"id":4090872,"accession":"0000902664-25-004662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-004662","line_url":"/filing/0000902664-25-004662#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":165667.0,"shares_display":"165,667","price_per_share":8.4005,"price_display":"8.40","price_state":"stated","total_value":1391685.6335,"total_display":"1,391,685.63","total_whole":"1,391,686","shares_owned_after":8963500.0,"shares_owned_after_display":"8,963,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-30","scope":"insider"},{"id":5021630,"accession":"0000902664-25-004536","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-004536","line_url":"/filing/0000902664-25-004536#line-1","is_derivative":false,"issuer_cik":"0001191070","issuer_name":"Neuphoria Therapeutics Inc.","issuer_ticker":"NEUP","issuer_name_source":null,"issuer_url":"/issuer/0001191070","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":639110.0,"shares_display":"639,110","price_per_share":5.137,"price_display":"5.14","price_state":"stated","total_value":3283108.07,"total_display":"3,283,108.07","total_whole":"3,283,108","shares_owned_after":875328.0,"shares_owned_after_display":"875,328","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-21","filed_date":"2025-10-23","scope":"insider"},{"id":5189790,"accession":"0000902664-25-004499","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000902664-25-004499","line_url":"/filing/0000902664-25-004499#line-4","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":32217.0,"shares_display":"32,217","price_per_share":7.8395,"price_display":"7.84","price_state":"stated","total_value":252565.1715,"total_display":"252,565.17","total_whole":"252,565","shares_owned_after":8797833.0,"shares_owned_after_display":"8,797,833","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-17","filed_date":"2025-10-21","scope":"insider"},{"id":5189785,"accession":"0000902664-25-004499","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-25-004499","line_url":"/filing/0000902664-25-004499#line-3","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":8.855,"price_display":"8.86","price_state":"stated","total_value":1328250.0,"total_display":"1,328,250.00","total_whole":"1,328,250","shares_owned_after":8765616.0,"shares_owned_after_display":"8,765,616","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-16","filed_date":"2025-10-21","scope":"insider"},{"id":5189781,"accession":"0000902664-25-004499","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-25-004499","line_url":"/filing/0000902664-25-004499#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":51500.0,"shares_display":"51,500","price_per_share":7.9427,"price_display":"7.94","price_state":"stated","total_value":409049.05,"total_display":"409,049.05","total_whole":"409,049","shares_owned_after":8615616.0,"shares_owned_after_display":"8,615,616","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-15","filed_date":"2025-10-21","scope":"insider"},{"id":5189775,"accession":"0000902664-25-004499","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-004499","line_url":"/filing/0000902664-25-004499#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15032.0,"shares_display":"15,032","price_per_share":7.587,"price_display":"7.59","price_state":"stated","total_value":114047.784,"total_display":"114,047.78","total_whole":"114,048","shares_owned_after":8564116.0,"shares_owned_after_display":"8,564,116","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-14","filed_date":"2025-10-21","scope":"insider"},{"id":4746623,"accession":"0000902664-25-004379","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-25-004379","line_url":"/filing/0000902664-25-004379#line-3","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":277298.0,"shares_display":"277,298","price_per_share":7.3617,"price_display":"7.36","price_state":"stated","total_value":2041384.6866,"total_display":"2,041,384.69","total_whole":"2,041,385","shares_owned_after":8549084.0,"shares_owned_after_display":"8,549,084","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-10","filed_date":"2025-10-10","scope":"insider"},{"id":4746621,"accession":"0000902664-25-004379","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-25-004379","line_url":"/filing/0000902664-25-004379#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":626043.0,"shares_display":"626,043","price_per_share":6.6958,"price_display":"6.70","price_state":"stated","total_value":4191858.7194,"total_display":"4,191,858.72","total_whole":"4,191,859","shares_owned_after":8271786.0,"shares_owned_after_display":"8,271,786","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-09","filed_date":"2025-10-10","scope":"insider"},{"id":4746615,"accession":"0000902664-25-004379","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-004379","line_url":"/filing/0000902664-25-004379#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Cullinan Therapeutics, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":556300.0,"shares_display":"556,300","price_per_share":6.46,"price_display":"6.46","price_state":"stated","total_value":3593698.0,"total_display":"3,593,698.00","total_whole":"3,593,698","shares_owned_after":7645743.0,"shares_owned_after_display":"7,645,743","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-08","filed_date":"2025-10-10","scope":"insider"},{"id":4697677,"accession":"0000902664-25-004079","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-25-004079","line_url":"/filing/0000902664-25-004079#line-3","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11900.0,"shares_display":"11,900","price_per_share":6.9895,"price_display":"6.99","price_state":"stated","total_value":83175.05,"total_display":"83,175.05","total_whole":"83,175","shares_owned_after":623704.0,"shares_owned_after_display":"623,704","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-15","filed_date":"2025-09-15","scope":"insider"},{"id":4697670,"accession":"0000902664-25-004079","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-25-004079","line_url":"/filing/0000902664-25-004079#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19783.0,"shares_display":"19,783","price_per_share":6.9908,"price_display":"6.99","price_state":"stated","total_value":138298.9964,"total_display":"138,299.00","total_whole":"138,299","shares_owned_after":611804.0,"shares_owned_after_display":"611,804","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-12","filed_date":"2025-09-15","scope":"insider"},{"id":4697662,"accession":"0000902664-25-004079","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-004079","line_url":"/filing/0000902664-25-004079#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (Common Stock)","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":325.0,"shares_display":"325","price_per_share":6.9558,"price_display":"6.96","price_state":"stated","total_value":2260.635,"total_display":"2,260.64","total_whole":"2,261","shares_owned_after":592021.0,"shares_owned_after_display":"592,021","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-15","scope":"insider"},{"id":4452462,"accession":"0000902664-25-003152","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-25-003152","line_url":"/filing/0000902664-25-003152#line-3","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":66423.0,"shares_display":"66,423","price_per_share":5.7127,"price_display":"5.71","price_state":"stated","total_value":379454.6721,"total_display":"379,454.67","total_whole":"379,455","shares_owned_after":591696.0,"shares_owned_after_display":"591,696","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-07-24","filed_date":"2025-07-24","scope":"insider"},{"id":4452457,"accession":"0000902664-25-003152","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-25-003152","line_url":"/filing/0000902664-25-003152#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":49302.0,"shares_display":"49,302","price_per_share":5.7408,"price_display":"5.74","price_state":"stated","total_value":283032.9216,"total_display":"283,032.92","total_whole":"283,033","shares_owned_after":525273.0,"shares_owned_after_display":"525,273","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-07-23","filed_date":"2025-07-24","scope":"insider"},{"id":4452451,"accession":"0000902664-25-003152","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-003152","line_url":"/filing/0000902664-25-003152#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13123.0,"shares_display":"13,123","price_per_share":5.4361,"price_display":"5.44","price_state":"stated","total_value":71337.9403,"total_display":"71,337.94","total_whole":"71,338","shares_owned_after":475971.0,"shares_owned_after_display":"475,971","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-07-22","filed_date":"2025-07-24","scope":"insider"},{"id":4697655,"accession":"0000902664-25-002511","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-25-002511","line_url":"/filing/0000902664-25-002511#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200000.0,"shares_display":"1,200,000","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":1440000.0,"total_display":"1,440,000.00","total_whole":"1,440,000","shares_owned_after":7946141.0,"shares_owned_after_display":"7,946,141","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-20","filed_date":"2025-05-21","scope":"insider"},{"id":4697647,"accession":"0000902664-25-002511","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-25-002511","line_url":"/filing/0000902664-25-002511#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1388794.0,"shares_display":"1,388,794","price_per_share":1.2,"price_display":"1.20","price_state":"stated","total_value":1666552.8,"total_display":"1,666,552.80","total_whole":"1,666,553","shares_owned_after":6746141.0,"shares_owned_after_display":"6,746,141","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-19","filed_date":"2025-05-21","scope":"insider"},{"id":3106478,"accession":"0000902664-24-007075","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-24-007075","line_url":"/filing/0000902664-24-007075#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":373645.0,"shares_display":"373,645","price_per_share":0.6451,"price_display":"0.65","price_state":"stated","total_value":241038.3895,"total_display":"241,038.39","total_whole":"241,038","shares_owned_after":9256953.0,"shares_owned_after_display":"9,256,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-27","filed_date":"2024-12-31","scope":"insider"},{"id":2035176,"accession":"0000902664-24-006934","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-24-006934","line_url":"/filing/0000902664-24-006934#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100000.0,"shares_display":"100,000","price_per_share":2.9014,"price_display":"2.90","price_state":"stated","total_value":290140.0,"total_display":"290,140.00","total_whole":"290,140","shares_owned_after":5357347.0,"shares_owned_after_display":"5,357,347","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-13","filed_date":"2024-12-16","scope":"insider"},{"id":2035175,"accession":"0000902664-24-006934","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-24-006934","line_url":"/filing/0000902664-24-006934#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31800.0,"shares_display":"31,800","price_per_share":3.0072,"price_display":"3.01","price_state":"stated","total_value":95628.96,"total_display":"95,628.96","total_whole":"95,629","shares_owned_after":5257347.0,"shares_owned_after_display":"5,257,347","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-12","filed_date":"2024-12-16","scope":"insider"},{"id":3149938,"accession":"0000902664-24-006799","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-24-006799","line_url":"/filing/0000902664-24-006799#line-3","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":29300.0,"shares_display":"29,300","price_per_share":0.6711,"price_display":"0.67","price_state":"stated","total_value":19663.23,"total_display":"19,663.23","total_whole":"19,663","shares_owned_after":8883308.0,"shares_owned_after_display":"8,883,308","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-27","filed_date":"2024-11-27","scope":"insider"},{"id":3149936,"accession":"0000902664-24-006799","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000902664-24-006799","line_url":"/filing/0000902664-24-006799#line-2","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":167055.0,"shares_display":"167,055","price_per_share":0.7075,"price_display":"0.71","price_state":"stated","total_value":118191.4125,"total_display":"118,191.41","total_whole":"118,191","shares_owned_after":8854008.0,"shares_owned_after_display":"8,854,008","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-26","filed_date":"2024-11-27","scope":"insider"},{"id":3149934,"accession":"0000902664-24-006799","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-24-006799","line_url":"/filing/0000902664-24-006799#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share (\"Common Stock\")","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":259998.0,"shares_display":"259,998","price_per_share":0.5641,"price_display":"0.56","price_state":"stated","total_value":146664.8718,"total_display":"146,664.87","total_whole":"146,665","shares_owned_after":8686953.0,"shares_owned_after_display":"8,686,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-25","filed_date":"2024-11-27","scope":"insider"},{"id":2380109,"accession":"0000902664-24-006718","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000902664-24-006718","line_url":"/filing/0000902664-24-006718#line-1","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Nichols Weston; Lynx1 Capital Management LP","owner_display_name":"Nichols Weston","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":947.0,"shares_display":"947","price_per_share":4.3442,"price_display":"4.34","price_state":"stated","total_value":4113.9574,"total_display":"4,113.96","total_whole":"4,114","shares_owned_after":5225547.0,"shares_owned_after_display":"5,225,547","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-15","filed_date":"2024-11-19","scope":"insider"},{"id":8645068,"accession":"0000902664-23-003407","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000902664-23-003407","line_url":"/filing/0000902664-23-003407","is_derivative":false,"issuer_cik":"0001746376","issuer_name":"TScan Therapeutics, Inc.","issuer_ticker":"TCRX","issuer_name_source":null,"issuer_url":"/issuer/0001746376","owner_cik":null,"owner_name":"Lynx1 Capital Management LP; Nichols Weston","owner_display_name":"Lynx1 Capital Management LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common stock, $0.0001 par value per share Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25400.0,"shares_display":"25,400","price_per_share":2.5178149606299214,"price_display":"2.52","price_state":"stated","total_value":63952.5,"total_display":"63,952.50","total_whole":"63,953","shares_owned_after":5240000.0,"shares_owned_after_display":"5,240,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-05-31","filed_date":"2023-06-02","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001703647","name":"Korro Bio, Inc.","url":"/issuer/0001703647","role":"Ten percent owner","n_filings":2,"first_seen":"2026-04-02","last_seen":"2026-08-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001787297","name":"Passage BIO, Inc.","url":"/issuer/0001787297","role":"Ten percent owner","n_filings":5,"first_seen":"2024-11-27","last_seen":"2026-06-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001783328","name":"TScan Therapeutics, Inc.","url":"/issuer/0001783328","role":"Ten percent owner","n_filings":5,"first_seen":"2023-06-02","last_seen":"2025-12-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001789972","name":"Cullinan Therapeutics, Inc.","url":"/issuer/0001789972","role":"Ten percent owner","n_filings":3,"first_seen":"2025-10-10","last_seen":"2025-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001191070","name":"Neuphoria Therapeutics Inc.","url":"/issuer/0001191070","role":"Ten percent owner","n_filings":1,"first_seen":"2025-10-23","last_seen":"2025-10-23"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001910456","retrieved_at":"2026-08-23T08:53:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}